ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES
DOI:
https://doi.org/10.56238/levv17n56-026Keywords:
Orforglipron, GLP-1, Type 2 Diabetes Mellitus, Obesity, Metabolic TherapyAbstract
Orforglipron (LY3502970) is the first small-molecule, non-peptidic oral agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed for the treatment of obesity and type 2 diabetes mellitus (T2DM). This study conducted a narrative literature review, of a descriptive and qualitative nature, aiming to compile and critically analyze scientific evidence published between 2015 and 2025 regarding the pharmacology, clinical efficacy, safety, and therapeutic applicability of this agent. The literature search was performed in PubMed, SciELO, ScienceDirect, and ClinicalTrials.gov, using controlled descriptors from the DeCS and MeSH vocabularies. A total of 19 studies, including randomized clinical trials, systematic reviews, and meta-analyses, were included. Findings demonstrated mean reductions in glycated hemoglobin (HbA1c) of 1.3–1.6% and body weight loss of 10–15%, with a favorable safety profile and mild to moderate gastrointestinal effects. Additionally, improvements were observed in cardiometabolic parameters, such as blood pressure, LDL cholesterol, and high-sensitivity C-reactive protein, suggesting a possible indirect cardioprotective effect. In conclusion, Orforglipron represents a significant innovation in metabolic therapy, combining clinical efficacy, dosing convenience, and potential cardiovascular benefit. However, its clinical consolidation will depend on the completion of ongoing phase 3 multicenter trials, which are expected to confirm its effects on long-term clinical outcomes.
Downloads
References
ALFARIS, R. A. et al. Comparative efficacy and safety of GLP-1 receptor agonists in type 2 diabetes: a systematic review and meta-analysis. Diabetes Research and Clinical Practice, v. 207, p. 110–122, 2024. DOI: 10.1016/j.diabres.2024.110122.
BRASIL. Conselho Nacional de Saúde. Resolução nº 510, de 7 de abril de 2016. Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais. Diário Oficial da União, Brasília, 24 maio 2016.
CHANDRAKUMAR, A. et al. Bariatric surgery and cardiovascular outcomes: a systematic review and meta-analysis. Journal of the American Heart Association, v. 12, n. 4, e027643, 2023. DOI: 10.1161/JAHA.122.027643.
DOUMOURAS, A. G. et al. Association between bariatric surgery and major adverse cardiovascular events in patients with obesity and diabetes mellitus: a population-based matched cohort study. Circulation, v. 143, n. 13, p. 1213–1225, 2021. DOI: 10.1161/CIRCULATIONAHA.120.050622.
DUTTA, D. et al. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obesity Science & Practice, v. 10, n. 2, p. 211–224, 2024. DOI: 10.1002/osp4.698.
FERNANDES CARDOSO, S.; SANTOS-FURTADO, M. Obesidade, inflamação e insuficiência cardíaca: uma revisão narrativa. Arquivos Brasileiros de Cardiologia, v. 113, n. 2, p. 238–246, 2019. DOI: 10.5935/abc.20190105.
GOGINENI, P. et al. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opinion on Pharmacotherapy, v. 25, n. 6, p. 801–818, 2024. DOI: 10.1080/14656566.2024.2403167.
IDRIS, I. Efficacy of a non-peptide GLP-1 analogue, Orforglipron, to induce weight loss reported in a phase 2 study. Diabetes, Obesity and Metabolism, v. 25, n. 3, p. 713–719, 2023. DOI: 10.1111/dom.15213.
KRISHNAN, S. et al. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with obesity and diabetes: a meta-analysis. Diabetes, Obesity and Metabolism, v. 27, n. 1, p. 54–66, 2025. DOI: 10.1111/dom.15545.
MA, X. et al. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered Orforglipron. Diabetes Therapy, v. 15, n. 3, p. 819–832, 2024. DOI: 10.1007/s13300-024-01524-8.
MAHAPATRA, S.; KARUPPASAMY, S. P.; SAHOO, J. P. GLP-1 receptor agonists in diabetes and obesity: emerging clinical evidence and pharmacological trends. Metabolic Medicine Journal, v. 13, n. 1, p. 77–92, 2022. DOI: 10.1093/metmed/jmac013.
MORSE, B. L. et al. Disposition and absolute bioavailability of orally administered Orforglipron in healthy participants. Clinical Pharmacology in Drug Development, v. 14, n. 1, p. 47–59, 2025. DOI: 10.1002/cpdd.1574.
OLIVEIRA, A. C.; ROSÁRIO, F. M. Impacto da cirurgia bariátrica nos desfechos cardiometabólicos em obesos graves: revisão sistemática. Revista da Associação Médica Brasileira, v. 68, n. 10, p. 1314–1323, 2022. DOI: 10.1590/1806-9282.20220510.
PACKER, M. et al. Tirzepatide and cardiovascular outcomes in patients with heart failure and obesity. New England Journal of Medicine, v. 392, p. 1234–1246, 2025. DOI: 10.1056/NEJMoa2500123.
PESSÔA COSTA, C. R. Cirurgia bariátrica e risco cardiovascular: análise de evidências contemporâneas. Revista Brasileira de Obesidade, Nutrição e Emagrecimento, v. 15, n. 93, p. 111–121, 2021.
ROTHER, E. T. Revisão sistemática X revisão narrativa. Acta Paulista de Enfermagem, v. 20, n. 2, p. v–vi, 2007. DOI: 10.1590/S0103-21002007000200001.
STEFANOU, M. I. et al. Dual GIP and GLP-1 receptor agonism with tirzepatide and cardiovascular outcomes: current evidence and perspectives. Diabetologia, v. 67, n. 3, p. 411–424, 2024. DOI: 10.1007/s00125-024-05984-2.
VAN VELDHUISEN, D. J. et al. Obesity, metabolic dysfunction, and heart failure with preserved ejection fraction: pathophysiology and therapeutic perspectives. European Heart Journal, v. 43, n. 12, p. 1127–1139, 2022. DOI: 10.1093/eurheartj/ehac032.
WHARTON, S. et al. Treatment with Orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of cardiovascular risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovascular Diabetology, v. 24, n. 1, p. 118–132, 2025. DOI: 10.1186/s12933-025-02044-6.
